The Blueprint Neurotherapeutics Network (BPN) offers this grant to neuroscience investigators aiming to advance small molecule drug discovery and development projects for nervous system disorders into clinical trials. This program supports activities conducted in applicants’ own laboratories, including disease-specific assays and models. Awardees benefit from collaboration with NIH-funded consultants and access to NIH Contract Research Organizations (CROs) for specialized services like medicinal chemistry, pharmacokinetics, toxicology, and Phase I clinical testing. Projects can initiate at the Discovery stage for hit compound optimization or directly at the Development stage, progressing through IND-enabling studies. Grantees retain intellectual property rights, ensuring control over drug candidates developed.
Opportunity ID: 325041
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-20-122 |
| Funding Opportunity Title: | Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health Income Security and Social Services |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.121 — Oral Diseases and Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Mar 03, 2020 |
| Last Updated Date: | Jun 28, 2023 |
| Original Closing Date for Applications: | May 07, 2023 |
| Current Closing Date for Applications: | Sep 07, 2023 |
| Archive Date: | Oct 07, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Private institutions of higher education County governments Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled “Additional Information on Eligibility” for clarification) State governments Small businesses Special district governments Independent school districts Public and State controlled institutions of higher education City or township governments Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
Reissue of PAR-18-546. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-20-122.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| updated close date | Jun 28, 2023 | |
| Mar 03, 2020 | ||
| Mar 06, 2020 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-20-122 |
| Funding Opportunity Title: | Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health Income Security and Social Services |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.121 — Oral Diseases and Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Mar 03, 2020 |
| Last Updated Date: | Jun 28, 2023 |
| Original Closing Date for Applications: | May 07, 2023 |
| Current Closing Date for Applications: | Sep 07, 2023 |
| Archive Date: | Oct 07, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Private institutions of higher education County governments Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled “Additional Information on Eligibility” for clarification) State governments Small businesses Special district governments Independent school districts Public and State controlled institutions of higher education City or township governments Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
Reissue of PAR-18-546. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-20-122.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-20-122 |
| Funding Opportunity Title: | Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health Income Security and Social Services |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.121 — Oral Diseases and Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 03, 2020 |
| Last Updated Date: | Mar 03, 2020 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | May 07, 2023 |
| Archive Date: | Jun 12, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Private institutions of higher education Native American tribal governments (Federally recognized) Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Others (see text field entitled “Additional Information on Eligibility” for clarification) State governments Small businesses City or township governments Independent school districts For profit organizations other than small businesses Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Reissue of PAR-18-546. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-20-122.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
DISPLAYING: Forecast 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | NOT-NS-20-033 |
| Funding Opportunity Title: | Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.121 — Oral Diseases and Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Forecast 1 |
| Posted Date: | Mar 06, 2020 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | – |
| Archive Date: | Mar 02, 2020 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities County governments Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) State governments Small businesses Independent school districts For profit organizations other than small businesses Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | – |
| Description: | The NIH announces its intention to reissue PAR-18-546 for investigators seeking support from the Blueprint Neurotherapeutics (BPN) Network. Applicants will be encouraged to utilize a customized set of contract resources, and consultants from the BPN Network to help advance their neuroscience-focused drug discovery and development projects into the clinic. This Notice is provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This FOA will utilize the UG3/UH3 activity code. Details of the planned FOA are provided below. The FOA is expected to be published in February of 2020 with an expected application due date in August 2020. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
–
Email:Email: cywincl@ninds.nih.gov |
Related Documents
Folder 325041 Full Announcement-PAR-20-122 -> PAR-20-122-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00258790 | Jul 11, 2020 | Jan 24, 2022 | View | |
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00270446 | Nov 18, 2021 | Jan 24, 2023 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00278417 | Nov 15, 2022 | Sep 07, 2023 | View |
Package 1
Mandatory forms
325041 RR_SF424_2_0-2.0.pdf
325041 PHS398_CoverPageSupplement_5_0-5.0.pdf
325041 RR_OtherProjectInfo_1_4-1.4.pdf
325041 PerformanceSite_2_0-2.0.pdf
325041 RR_KeyPersonExpanded_2_0-2.0.pdf
325041 RR_Budget_1_4-1.4.pdf
325041 PHS398_ResearchPlan_4_0-4.0.pdf
325041 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
325041 RR_SubawardBudget30_1_4-1.4.pdf
325041 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
325041 RR_SF424_5_0-5.0.pdf
325041 PHS398_CoverPageSupplement_5_0-5.0.pdf
325041 RR_OtherProjectInfo_1_4-1.4.pdf
325041 PerformanceSite_4_0-4.0.pdf
325041 RR_KeyPersonExpanded_4_0-4.0.pdf
325041 RR_Budget_3_0-3.0.pdf
325041 PHS398_ResearchPlan_4_0-4.0.pdf
325041 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
325041 RR_SubawardBudget30_3_0-3.0.pdf
325041 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 3
Mandatory forms
325041 RR_SF424_5_0-5.0.pdf
325041 PHS398_CoverPageSupplement_5_0-5.0.pdf
325041 RR_OtherProjectInfo_1_4-1.4.pdf
325041 PerformanceSite_4_0-4.0.pdf
325041 RR_KeyPersonExpanded_4_0-4.0.pdf
325041 RR_Budget_3_0-3.0.pdf
325041 PHS398_ResearchPlan_5_0-5.0.pdf
325041 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
325041 RR_SubawardBudget30_3_0-3.0.pdf
325041 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
